Jong-Sung Koh

Jong-Sung Koh is a prominent inventor based in Bucheon-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific diseases. With a total of 2 patents to his name, Koh's work is recognized for its innovative approaches and practical applications.

Latest Patents

Koh's latest patents include a crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6H)-one hydrochloride. This invention relates to a crystal polymorph that effectively suppresses FLT3 and demonstrates excellent stability even in high temperature and humid environments. Additionally, he has developed substituted pyrazoles as LRRK2 inhibitors, which include a pyrrolo(pyrazolo)pyrimidine compound that shows excellent LRRK2 inhibitory activity. The patent also covers methods for manufacturing the compound and its uses in treating or preventing degenerative brain diseases.

Career Highlights

Koh is currently employed at Oscotec Inc., where he continues to advance his research and development efforts. His work at Oscotec has positioned him as a key player in the pharmaceutical industry, contributing to innovative solutions for complex health issues.

Collaborations

Koh collaborates with notable colleagues, including Jung-Ho Kim and Jang-Sik Choi. These partnerships enhance the research environment and foster the development of groundbreaking pharmaceutical solutions.

Conclusion

Jong-Sung Koh's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His innovative work continues to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.